These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Rice GP; Casali P; Merigan TC; Oldstone MB Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954 [TBL] [Abstract][Full Text] [Related]
8. The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis. Hirsch RL; Johnson KP Neurology; 1985 Apr; 35(4):597-600. PubMed ID: 3982654 [TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group. J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737 [TBL] [Abstract][Full Text] [Related]
10. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915 [TBL] [Abstract][Full Text] [Related]
11. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. Kastrukoff LF; Morgan NG; Aziz TM; Zecchini D; Berkowitz J; Paty DW J Neuroimmunol; 1988 Nov; 20(1):15-23. PubMed ID: 3183034 [TBL] [Abstract][Full Text] [Related]
12. Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Nortvedt MW; Riise T; Myhr KM; Nyland HI; Hanestad BR Mult Scler; 1999 Oct; 5(5):317-22. PubMed ID: 10516774 [TBL] [Abstract][Full Text] [Related]
14. Alpha interferon clinical trial for multiple sclerosis: design considerations. Alter M; Greenstein J; Camenga D; LaRue L Neuroepidemiology; 1987; 6(1-2):85-92. PubMed ID: 3306431 [TBL] [Abstract][Full Text] [Related]
15. Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. Durelli L; Bongioanni MR; Ferrero B; Imperiale D; Verdun E; Oggero A; Gentile E; Bradac GB; Bergui M; Bergamini L; Bergamasco B Mult Scler; 1996 Jul; 1(6):366-71. PubMed ID: 9345419 [TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S; Rahimi R; Abdollahi M Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]